Hiramatsu M, Hayashi A, Hidaka H, Ueshima H, Kanno T
Minase Research Institute, Ono Pharmaceutical Company Ltd., Osaka, Japan.
Clin Chem. 1998 Oct;44(10):2152-7.
We have developed an enzyme immunoassay for mevalonic acid (MVA), using a specific monoclonal antibody. The intra- and interassay coefficients of variation calculated on two urine samples were 3.3% and 3.4%, respectively, in the intraassay precision test and 3.5% and 6.9% in the interassay evaluation. Pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, was administered to nine healthy men, and in all cases, their MVA excretion rates then decreased. The more MVA that was excreted in the urine before the pravastatin administration, the greater a reduction of MVA excretion was observed. The daily MVA excretions in healthy men (n = 120) and women (n = 105) were 2.32 micromol/day (SD, 0.82 micromol/day) and 1.85 micromol/day (SD, 0.47 micromol/day), respectively. In streptozotocin-induced diabetic rats (n = 14), the plasma cholesterol concentrations and MVA excretion rates were increased, and a positive correlation was observed between the plasma cholesterol and the urinary MVA concentrations.
